Introduction {#Sec1}
============

Tubulointerstitial fibrosis, the loss of renal tubules and accumulation of extracellular matrix (ECM) proteins leads to end stage renal failure \[[@CR1], [@CR2]\]. Although tubular epithelial cells can synthesize numerous ECM proteins \[[@CR3], [@CR4]\], myofibroblasts are apparently the main sources of increased ECM deposition in renal fibrosis \[[@CR4]--[@CR6]\]. Previous studies have demonstrated that interstitial myofibroblasts derive from the differentiation of fibroblasts, migration of perivascular smooth muscle cells, or local proliferation \[[@CR7]--[@CR10]\]. Tubular epithelial cells can also transdifferentiate into myofibroblasts under pathological conditions, such as those present during tubulointerstitial fibrosis. TGF-β1 is a key cytokine that regulates the progression of tubulointerstitial fibrosis \[[@CR11]\].

The P311 protein, also known as the binding protein of TGF-β LAP, is an 8-kD protein originally found in neurons and muscle. A recent study showed that expression of P311 in NIH3T3 cells induced a myofibroblast phenotype with low TGF-β1 expression \[[@CR12]\]. Some researchers have suggested that P311 is involved in TGF-β1-independent myofibroblast transformation and in the progression of fibrosis \[[@CR13]\]. However, it is unknown whether P311 has a role in the progression of renal tubulointerstitial fibrosis, especially in IgA nepropathy (IgAN).

IgAN is the most common form of primary glomerulonephritis. Renal tubulointerstitial fibrosis is an important process in the progression of IgAN \[[@CR14]\]. The pathogenesis of IgAN involves activation of mesangial cells and secretion of cytokines, such as TGF-β1 and IL-1, which enhance cell proliferation, trans-differentiation, and accumulation of ECM, eventually leading to tubulointerstitial fibrosis \[[@CR15]\]. However, no studies have examined the expression of P311 in tubulointerstitial tissue and the relationship of P311, TGF-β1, and the clinical features of IgAN patients. In this study, we measured the expression of P311 and TGF-β1 in biopsy samples of IgAN patients, and analyzed the relationship between these proteins and clinical data.

Methods {#Sec2}
=======

Patients and design {#Sec3}
-------------------

Fifty-seven IgAN patients were included in the present study. The diagnosis of primary IgAN was based on renal biopsy findings including a predominance of IgA deposits in the glomerular mesangial areas as detected by immunofluorescence. Patients with systemic disease such as Schönlein Henoch purpura, systemic lupus erythematosus, rheumatoid arthritis, diabetes mellitus, and liver cirrhosis were excluded. Five adult kidney tissues from partial nephrectomy for incidentaloma were included as controls.

The severity of pathological changes was graded according to Lee's classification \[[@CR16], [@CR17]\]. Grades I and II were considered as mild; grades III as moderate; grades IV and V as severe. The severity of tubulointerstitial lesions was graded according to the Katafuchi classification \[[@CR18]\]. Cumulative score ranging from 1 to 3 was considered as mild (group I), cumulative score ranging from 4 to 6 as moderate (group II), and cumulative score ranging from 7 to 9 as severe (group III).

The severity of proteinuria was classified according to 24-h urine protein excretion: \<1 g as mild; 1--3 g as moderate; \>3 g as severe. A patient with systolic blood pressure \>130 mmHg or diastolic blood pressure \>80 mmHg was considered hypertensive. Serum creatinine (Scr) level of 133 μmol/L was considered the upper normal limit. The equation developed by the MDRD Study Group was used to calculate eGFR \[[@CR19]\]. Then, patients were divided into different subgroups (Scr \> 133 μmol/L group vs. Scr \< 133 μmol/L; eGFR \< 59 mL/min/1.73 m^2^ vs. eGFR ≥ 60 mL/min/1.73 m^2^). The Sichuan University Ethics Committee approved this study, and all participants gave informed consent.

Immunohistochemistry {#Sec4}
--------------------

Immunohistochemistry was performed on paraffin-embedded tissue sections using polyclonal antibodies against P311 and TGF-β1. Formalin-fixed, paraffin-embedded tissue samples were examined. Sections (3 μm thick) were mounted on polylysine-coated slides and deparaffinized. Antigen retrieval was performed by microwave heating for 4 × 5 min cycles in a citrate buffer (0.01 mol/L, pH 6.0). After washing with PBS, endogeneous peroxidase activity was blocked by incubating with 0.03% H~2~O~2~ for 10 min, and sections were washed with PBS again. Then sections were treated with 10% normal goat serum for 2 h and incubated overnight at 4°C with anti-P311 polyclonal antibody (Biosynthesis Biotechnology, BIOS, China) or anti-TGF-β1 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing with PBS, sections were incubated with HRP-labeled goat anti-rabbit P311 or TGF-β1 antibodies (Biosynthesis Biotechnology, BIOS, China) for 1 h. After washing again with PBS, sections were exposed to DAB for 15 min, counterstained with Mayer's hematoxylin, and then mounted. We used single (no primary antibody) and double (no primary and no secondary antibody) negative controls. Red-brown granular cytoplasmic staining was considered as positive.

Statistical analysis {#Sec5}
--------------------

Image-Pro Plus 6.0 was used to analyze the immunostaining results. All data are presented as means ± SDs. Statistical comparisons (correlation analysis, ANOVA, and Student's *t*-test) were performed with SPSS 13.0 software. The *r* value represents the correlation coefficient based on Pearson's test, and a *P* value less than 0.05 was considered significant.

Results {#Sec6}
=======

Clincal data {#Sec7}
------------

Kidney specimens from 57 IgAN patients and five incidentaloma patients (controls) were analyzed. According to Lee's pathological grading, specimens were classified as control, mild, moderate, or severe. Table [1](#Tab1){ref-type="table"} shows the clinical data of patients in these groups. ANOVA analysis indicated significant differences in proteinuria, eGFR, and Scr among these four groups (*P* \< 0.05).Table 1Relevant clinical data of subgroups according to Lee's pathological gradingObjectControlLee's pathological gradingMildModerateSevereNumber5272010Age (years)33.00 ± 6.2931.22 ± 10.7639.40 ± 13.9635.30 ± 10.22Males/females1/410/1711/96/4Blood pressure systolic (mmHg)114.40 ± 8.68110.09 ± 35.19126.19 ± 22.44134.15 ± 23.66Blood pressure diastolic (mmHg)87.80 ± 6.0671.99 ± 25.6283.06 ± 17.9187.60 ± 18.58Proteinuria quantification (g per 24 h)0.20 ± 0.082.72 ± 2.332.41 ± 1.61^a^4.69 ± 2.35^a,b^Severe proteinuria rate (%)03.3330.0070.00Serum creatinine (μmol/L)56.12 ± 11.4792.63 ± 49.42107.05 ± 28.51^a^201.37 ± 244.05^a,b^Renal dysfuntion rate (%)03.7015.0040.00GFR (ml/min)--81.84 ± 32.4662.69 ± 16.40^a^48.39 ± 19.35^a,b^Expressed as mean ± SD^a^Compared with mild group, *P* \< 0.05^b^Compared with moderate group, *P* \< 0.05

Based on Katafuchi pathological cumulative scores, kidney specimens were classified as control, group-I, group-II, or group-III. Table [2](#Tab2){ref-type="table"} shows the clinical data of patients in these groups. ANOVA analysis indicated significant differences in eGFR, Scr, and proteinuria among these four groups (*P* \< 0.05).Table 2Relevant clinical data of subgroups according to Katafuchi pathological cumulative scoresObjectControlKatafuchi pathological cumulative scoresIIIIIINumber533195Age (years)33.00 ± 6.2931.55 ± 10.9240.21 ± 13.1435.80 ± 12.13Males/females1/413/2010/94/1Blood pressure systolic (mmHg)114.40 ± 8.68110.84 ± 32.98130.04 ± 21.48141.85 ± 22.61Blood pressure diastolic (mmHg)86.80 ± 6.0673.52 ± 26.2985.74 ± 12.6485.15 ± 20.25Proteinuria quantification (g per 24 h)0.20 ± 0.082.47 ± 1.823.24 ± 2.15^a^5.06 ± 3.78^a,b^Severe proteinuria rate (%)030.3042.1180.00Serum creatinine (μmol/L)56.12 ± 11.4789.41 ± 42.72113.98 ± 28.14^a^307.92 ± 325.57^a,b^Renal dysfuntion rate (%)03.0321.0580.00GFR (ml/min)--81.96 ± 28.6353.95 ± 13.92^a^43.52 ± 25.24^a,b^Expressed as mean ± SD^a^Compared with mild group, *P* \< 0.05^b^Compared with moderate group, *P* \< 0.05

Expression of P311 {#Sec8}
------------------

Immunohistochemical results indicated that P311 was not present in the renal interstitium of normal renal tissues (Fig. [1](#Fig1){ref-type="fig"}a). In other words, P311 is not normally expressed by the tubular epithelial cells and endothelial cells that line the glomerular and peritubular capillaries. In contrast, there was significant staining for P311 in the tubular epithelial cells of IgAN patients (Fig. [2](#Fig2){ref-type="fig"}a, b, c). There was a significant difference in the expression of P311 in normal and IgAN patients (*P* \< 0.01). Interestingly, P311 was not detected in the renal glomerulus of IgAN patients or controls (Fig. [2](#Fig2){ref-type="fig"}d).Fig. 1Immunostaining of P311 (**a**) and TGF-β1 (**b**) in normal renal tissues. Magnification: ×200. Results are from representative sections of controlsFig. 2Immunostaining of P311 in the renal tissues of patients with different grades of IgA nephropathy. Tubulointerstitial tissue of a patient from the (**a**) severe fibrosis group, (**b**) moderate fibrosis group, (**c**) mild fibrosis group, and the (**d**) renal glomerulus of a patient from IgAN. The staining of P311 in tubular epithelial cells increases with the degree of tubulointerstitial fibrosis (**a**--**c**), but there is no P311 staining in renal glomerulus from IgAN (**d**). Magnification: ×200. Results are from representative sections of different groups

ANOVA analysis was performed for the four groups classified by Lee's pathological grading (Table [3](#Tab3){ref-type="table"}) and the four groups classified by Katafuchi pathological cumulative scores (Table [4](#Tab4){ref-type="table"}). The results showed that the expression of P311 increased as the extent of tubulointerstitial fibrosis increased.Table 3Expression of P311 and TGF-β1 of subgroups according to Lee's pathological gradingObjectControl *n* = 5Lee's pathological gradingMild, *n* = 27Moderate, *n* = 20Severe, *n* = 10Score of staining intensity for P31101.95 ± 2.755.00 ± 7.86^c^20.09 ± 15.78^a,b^Score of staining intensity for TGF-β11.08 ± 1.142.42 ± 3.215.73 ± 9.22^c^26.49 ± 25.41^a,b^Expressed as mean ± SD^a^Compared with mild group, *P* \< 0.05^b^Compared with moderate group, *P* \< 0.05^c^Compared with mild group, *P* \> 0.05Table 4Expression of P311 and TGF-β1 of subgroups according to Katafuchi pathological cumulative scoresObjectControl *n* = 5Katafuchi pathological cumulative scoresI, *n* = 33II, *n* = 19III, *n* = 5Score of staining intensity for P31102.53 ± 3.727.58 ± 12.48^c^25.23 ± 11.40^a,b^Score of staining intensity for TGF-β11.08 ± 1.144.23 ± 9.529.78 ± 18.22^c^23.87 ± 18.67^a,b^Expressed as mean ± SD^a^Compared with group I, *P* \< 0.05^b^Compared with group II, *P* \< 0.05^c^Compared with group I, *P* \> 0.05

Expression of TGF-β1 {#Sec9}
--------------------

There was weak staining of TGF-β1 in the interstitium of normal renal tissues (Fig. [1](#Fig1){ref-type="fig"}b) but significantly greater staining of TGF-β1 in the interstitium of IgAN patients (Fig. [3](#Fig3){ref-type="fig"}a, b, c). TGF-β1 was also present in the glomeruli of IgAN patients (Fig. [3](#Fig3){ref-type="fig"}d).Fig. 3Immunostaining of TGF-β1 in the renal tissues of patients with IgA nephropathy. Tubulointerstitial tissue of a patient from the (**a**) severe fibrosis group, (**b**) moderate fibrosis group, (**c**) mild fibrosis group, and the (**d**) renal glomerulus of a patient from IgAN. As with P311 (Fig. [2](#Fig2){ref-type="fig"}), staining of TGF-β1 in tubular epithelial cells increases with the degree of tubulointerstitial fibrosis (**a**--**c**). There is weak TGF-β1 staining in the renal glomerulus from IgAN (**d**). Magnification: ×200. Results are from representative sections of different groups

As mentioned earlier, ANOVA analysis was performed for the four groups classified by Lee's pathological grading (Table [3](#Tab3){ref-type="table"}) and the four groups classified by Katafuchi pathological cumulative scores (Table [4](#Tab4){ref-type="table"}). The results showed that expression of TGF-β1 increased as the extent of tubulointerstitial fibrosis increased.

Relationship between P311 and TGF-β1 expression {#Sec10}
-----------------------------------------------

We also analyzed the relationship between the expression of P311 and TGF-β1. Our results indicate that the expression of P311 correlated with the expression of TGF-β1 (*r* = 0.921, *P* \< 0.001) and that they had similar intracellular locations.

P311 expression and proteinuria {#Sec11}
-------------------------------

A total of 24 of 57 IgAN patients had severe proteinuria (\>3 g per 24 h), 24 had moderate proteinuria (1--3 g per 24 h), and 9 had mild proteinuria (\<1 g per 24 h). ANOVA showed that P311 expression was higher as the severity of proteinuria increased (Table [5](#Tab5){ref-type="table"}). In addition, there was a significant correlation between the amount of 24-h urine protein and P311 expression (*r* = 0.291, *P* \< 0.05).Table 5Expression of P311 in different subgroups according to proteinuria severityObjectControl *n* = 5Proteinuria severityMild, *n* = 33Moderate, *n* = 19Severe, *n* = 5Score of staining intensity for P31102.73 ± 3.369.19 ± 8.37^c^18.83 ± 10.07^a,b^Expressed as mean ± SD^a^Compared with mild group, *P* \< 0.05^b^Compared with moderate group, *P* \< 0.05^c^Compared with mild group, *P* \> 0.05

P311 expression and serum creatinine {#Sec12}
------------------------------------

A total of 19 of 57 IgAN patients had renal dysfunction (Scr \> 133 μmol/L) before biopsy. The renal P311 expression in these patients was significantly higher than in the remaining 38 IgAN patients (14.59 ± 15.01% vs. 4.63 ± 8.63%, *P* \< 0.05). However, P311 expression was not significantly correlated with the level of serum creatinine (*r* = 0.232, *P* \> 0.05).

P311 expression and eGFR {#Sec13}
------------------------

In the present study, 6 IgAN patients had eGFRs greater than 90 mL/min/1.73 m^2^, 34 patients had eGFRs of 60--89 mL/min/1.73 m^2^, 15 patients had eGFRs of 30--59 mL/min/1.73 m^2^, and 2 patients had eGFRs less than 29 mL/min/1.73 m^2^. We found that the mean level of P311 protein was higher in patients with eGFR \< 59 mL/min/1.73 m^2^ than in those with eGFR ≥ 60 mL/min/1.73 m^2^, but this difference was not significant (4.43 ± 9.18% vs. 8.83 ± 11.69%, *P* \> 0.05). P311 expression was not correlated with eGFR (*r* = 0.181, *P* \> 0.05).

P311 expression and other clinical data {#Sec14}
---------------------------------------

A total of 14 IgAN patients had hypertension before biopsy. A comparison of P311 expression in patients with or without hypertension indicated a significant difference (12.74 ± 14.82% vs. 4.09 ± 8.82%, *P* \< 0.05). However, there was no significant correlation between P311 expression and blood pressure (*r* = 0.201, *P* \> 0.05). In addition, there was no significant correlation between P311 expression and patients age (*r* = 0.137, *P* \> 0.05).

Discussion {#Sec15}
==========

IgAN is the most common form of primary glomerulonephritis. The pathogenesis of IgAN involves activation of mesangial cells and secretion of cytokines such as TGF-β1 and IL-1 \[[@CR20], [@CR21]\]. Tubular epithelial cells can transdifferentiate into myofibroblasts following stimulation by these cytokines, resulting in increased ECM deposition in tubulointerstitial tissue. The secretion of these cytokines, tubular epithelial myofibroblast trans-differentiation, and the accumulation of ECM eventually lead to tubulointerstitial fibrosis. In IgAN, tubulointerstitial fibrosis is considered to be the final pathway that leads to end stage renal failure \[[@CR1]\]. Progressive renal insufficiency develops in about 40% of IgAN patients 25 or more years after initial diagnosis \[[@CR15]\].

Numerous cytokines are involved in the progression of tubulointerstitial fibrosis \[[@CR22]\], and TGF-β1 is one of the most important cytokines controlling this process. There is a close relationship between the level of TGF-β1 and the progression of tubulointerstitial fibrosis \[[@CR11], [@CR23]\]. TGF-β1 promotes tubular epithelial myofibroblast trans-differentiation \[[@CR11]\] and increases the synthesis and accumulation of ECM proteins \[[@CR6]\].

TGF-β1 is a multi-functional cytokine that is secreted within tissues as a biologically inactive complex with LAP. It becomes functionally active after extracellular modification. After post-translational processing, TGF-β1 binds non-covalently to LAP to confer latency. The non-covalent interactions between TGF-β1 and LAP can be disrupted in vitro by heat, extremes of pH, and other chaotropic factors. However, in vivo, the disruption of the LAP and TGF-β1 complex appears central to activation. Following the cleavage of LAP, the inactive latent complex of TGF-β1 is converted into a mature functional protein. Several studies indicate that LAP may also be important in certain pathological processes. Zhang et al. showed that LAP can inhibit some TGF-β1 signals that have a role in fibrosis \[[@CR24]\]. A recent study found that LAP has chemotactic and anti-inflammatory activities that are independent of the presence of active TGF-β1 \[[@CR25]\].

P311 is an intracytoplasmic protein originally found in neurons and muscle that can bind to TGF-β LAP \[[@CR12]\]. P311 does not belong to any established protein family, and its biological function remains largely unknown. In cultured NIH3T3 cells, P311 binds to LAP and induces a myofibroblast phenotype, upregulates α-SMA, induces FGF-2, VEGF, and PDGF receptor, upregulates integrins α3 and α5, and increases cell proliferation \[[@CR12]\]. The in vitro P311-mediated changes differ from the well-characterized myofibroblast trans-differentiation, in that P311 inhibits the expression of TGF-β1 and TGF-β2 \[[@CR13]\]. These results suggested P311 is involved in the progression of fibrosis, but it is unknown whether P311 is also involved in the progression of renal tubulointerstitial fibrosis, especially in the kidneys of IgAN patients.

Heretofore, no studies have examined whether P311 is expressed in the tubulointerstitial tissue of IgAN patients, and there are no reports on the relationship between P311, TGF-β1, and clinical data of patients with IgAN.

Our study shows that expression of P311 in the kidneys of IgAN patients was significantly higher than in normal controls. In addition, greater expression of P311 was present in the kidneys of patients with more advanced tubulointerstitial fibrosis. The mechanism of P311 upregulation in the tubulointerstitial tissues of IgAN patients remains unknown. In the early stages of IgAN, a patient is in a proinflammatory state, so this is one possible reason for P311 upregulation.

The expression of TGF-β1 was also elevated in the kidneys of IgAN patients. Interestingly, the expression of P311 correlated with the expression of TGF-β1, and both occurred at similar locations within cells. It has been demonstrated previously that TGF-β1 is a key mediator in renal fibrotic progression \[[@CR11], [@CR23]\]. In the present study, our results suggest that P311 and TGF-β1 may bind to one another and thereby induce tubulointerstitial fibrosis in patients with IgAN.

In the early stages of IgAN, the patient is in a proinflammatory state, resulting in cell proliferation and secretion of cytokines such as TGF-β, IL-1, and CTGF. At the same time, the proinflammatory state induces upregulation of P311. Considering that P311 binds to TGF-β1 LAP, it may contribute to the progression of tubulointerstitial fibrosis by several mechanisms. One possibility is that P311 binds to TGF-β1 LAP, changes the conformation of LAP, and depresses LAP function. LAP bound to P311 could not inhibit TGF-β1 signals that result in fibrosis, and could not block inflammation. Thus, LAP bound to P311 would facilitate inflammation and fibrosis. Another possibility is that elevation of P311 contributes to activation of latent TGF-β1. Integrins are crucial for the activation of latent TGF-β1 \[[@CR26]\] and elevated P311 induces upregulation of α-SMA, induction of integrins, and increased cell proliferation \[[@CR12]\], which promotes the activation of latent TGF-β1. The active form of TGF-β1 promotes tubular epithelial myofibroblast trans-differentiation, enhances the synthesis of ECM proteins, and leads to tubulointerstitial fibrosis.

A second important finding in this study is that there was a correlation of P311 expression with various clinical parameters. Among our IgAN patients, there was a significant correlation between 24-h proteinuria and expression of P311, and between P311 expression and extent of tubulointerstitial fibrosis. This suggests that P311 might be involved in the progression of IgAN. Although the expression of P311 in patients with Scr \> 133 μmol/L was significantly higher than in patients with Scr \< 133 μmol/L and normal controls, P311 expression was not correlated with eGFR or Scr. This study also showed that expression of P311 and TGF-β1 in tubulointerstitial tissue from IgAN patients was higher than that of control patients, and that expression of these two proteins correlated with various clinical parameters and kidney lesion classification.

Finally, there is no indication that our findings would be specific for patients with IgAN. In fact, P311 expression may also be induced in the kidneys of patients with other renal diseases or renal damage, such as acute tubular necrosis or lupus nephritis. Studies are currently in progress to measure the expression of P311 in patients with other kidney impairments and to identify the role of P311 in the pathogenesis of IgAN.

We have had no involvements that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated. The results presented in this paper have not been published previously in whole or part.
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